

Adamas Pharmaceuticals Inc  
Form 4  
March 19, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Went Gregory T

(Last) (First) (Middle)

C/O ADAMAS  
PHARMACEUTICALS, INC., 1900  
POWELL ST., SUITE 750

(Street)

EMERYVILLE, CA 94608

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
Adamas Pharmaceuticals Inc  
[ADMS]

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/17/2015

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)

Chief Executive Officer

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	03/17/2015		M		1,900	A	\$ 1.875	1,908 <sup>(1)</sup>	D
Common Stock	03/17/2015		S		1,900	D	\$ 18	8 <sup>(1)</sup>	D
Common Stock	03/17/2015		S		2,700	D	\$ 18	417,748	I
									Gregory T Went & Marjorie S Went ttees Went Family

Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

									Living Trust dtd 03/24/11
Common Stock	03/18/2015	M	4,600	A	\$ 1.875	4,608 <sup>(1)</sup>	D		
Common Stock	03/18/2015	S	4,600	D	\$ 18.0007 <sup>(2)</sup>	8 <sup>(1)</sup>	D		
Common Stock	03/18/2015	S	9,420	D	\$ 18.0045 <sup>(3)</sup>	408,328	I		Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11
Common Stock	03/19/2015	M	12,320	A	\$ 1.875	12,328 <sup>(1)</sup>	D		
Common Stock	03/19/2015	S	2,320	D	\$ 18	10,008 <sup>(1)</sup>	D		
Common Stock	03/19/2015	S	2,148	D	\$ 18	406,180	I		Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11
Common Stock						6,666	I		Gregory T Went Cust - Bridget Went Under CA Uniform Transfers to Minors Act
Common Stock						6,666	I		Gregory T Went Cust - Cora Went Under CA Uniform Transfers to Minors

Common Stock	80,000	I	Act Gregory T Went & Marjorie S Went tees 2012 Irr Trust FBO Bridget Elise Went
Common Stock	80,000	I	Gregory T Went & Marjorie S Went tees 2012 Irr Trust FBO Cora Margaret Went

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to Buy)	\$ 1.875	03/17/2015		M	1,900	<u>(4)</u> 09/12/2016	Common Stock	1,900
Stock Option (Right to Buy)	\$ 1.875	03/18/2015		M	4,600	<u>(4)</u> 09/12/2016	Common Stock	4,600

Stock									
Option	\$ 1.875	03/19/2015		M	12,320	<u>(4)</u>	09/12/2016	Common	12,320
(Right to Buy)								Stock	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Went Gregory T C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE, CA 94608	X	X	Chief Executive Officer	

## Signatures

/s/Grace Shin, as  
Attorney-in-Fact

03/19/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

(2) The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from \$18.00 to 18.02, inclusive.

(3) The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from \$18.00 to 18.09, inclusive.

(4) This option is fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.